|
1
|
DeFronzo RA and Tripathy D: Skeletal
muscle insulin resistance is the primary defect in type 2 diabetes.
Diabetes Care. 32:S157–S163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosma M, Kersten S, Hesselink MK and
Schrauwen P: Re-evaluating lipotoxic triggers in skeletal muscle:
relating intramyocellular lipid metabolism to insulin sensitivity.
Prog Lipid Res. 51:36–49. 2012. View Article : Google Scholar
|
|
3
|
Muoio DM: Revisiting the connection
between intramyocellular lipids and insulin resistance: a long and
winding road. Diabetologia. 55:2551–2554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mingrone G, Rosa G, Greco AV, Manco M,
Vega N, Nanni G, Castagneto M and Vidal H: Intramyocitic lipid
accumulation and SREBP-1c expression are related to insulin
resistance and cardiovascular risk in morbid obesity.
Atherosclerosis. 170:155–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimano H: SREBP-1c and TFE3, energy
transcription factors that regulate hepatic insulin signalling. J
Mol Med. 85:437–444. 2007. View Article : Google Scholar
|
|
6
|
Raghow R, Yellaturu C, Deng X, Park EA and
Elam MB: SREBPs: the crossroads of physiological and pathological
lipid homeostasis. Trends Endocrinol Metab. 19:65–73. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bi Y, Wu W, Shi J, et al: Role for sterol
regulatory element binding protein-1c activation in mediating
skeletal muscle insulin resistance via repression of rat insulin
receptor substrate-1 transcription. Diabetologia. 57:592–602. 2014.
View Article : Google Scholar
|
|
8
|
Mantovani J and Roy R: Re-evaluating the
general(ized) roles of AMPK in cellular metabolism. FEBS Lett.
585:967–972. 2011. View Article : Google Scholar
|
|
9
|
Friedrichsen M, Mortensen B, Pehmøller C,
Birk JB and Wojtaszewski JF: Exercise-induced AMPK activity in
skeletal muscle: role in glucose uptake and insulin sensitivity.
Mol Cell Endocrinol. 366:204–214. 2013. View Article : Google Scholar
|
|
10
|
Musi N, Hirshman MF, Nygren J, et al:
Metformin increases AMP-activated protein kinase activity in
skeletal muscle of subjects with type 2 diabetes. Diabetes.
51:2074–2081. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou G, Myers R, Li Y, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sajan MP, Bandyopadhyay G, Miura A, et al:
AICAR and metformin, but not exercise, increase muscle glucose
transport through AMPK-, ERK-, and PDK1-dependent activation of
atypical PKC. Am J Physiol Endocrinol Metab. 298:E179–E192. 2010.
View Article : Google Scholar :
|
|
13
|
Yang J, Craddock L, Hong S and Liu ZM:
AMP-activated protein kinase suppresses LXR-dependent sterol
regulatory element-binding protein-1c transcription in rat hepatoma
McA-RH7777 cells. J Cell Biochem. 106:414–426. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yap F, Craddock L and Yang J: Mechanism of
AMPK suppression of LXR-dependent Srebp-1c transcription. Int J
Biol Sci. 7:645–650. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Xu S, Mihaylova MM, et al: AMPK
phosphorylates and inhibits SREBP activity to attenuate hepatic
steatosis and atherosclerosis in diet-induced insulin-resistant
mice. Cell Metab. 13:376–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jung EJ, Kwon SW, Jung BH, Oh SH and Lee
BH: Role of the AMPK/SREBP-1 pathway in the development of orotic
acid-induced fatty liver. J Lipid Res. 52:1617–1625. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rachek LI, Musiyenko SI, LeDoux SP and
Wilson GL: Palmitate induced mitochondrial deoxyribonucleic acid
damage and apoptosis in L6 rat skeletal muscle cells.
Endocrinology. 148:293–299. 2007. View Article : Google Scholar
|
|
18
|
Dimopoulos N, Watson M, Sakamoto K and
Hundal HS: Differential effects of palmitate and palmitoleate on
insulin action and glucose utilization in rat L6 skeletal muscle
cells. Biochem J. 399:473–481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hirabara SM, Silveira LR, Abdulkader F,
Carvalho CR, Procopio J and Curi R: Time-dependent effects of fatty
acids on skeletal muscle metabolism. J Cell Physiol. 210:7–15.
2007. View Article : Google Scholar
|
|
20
|
Zhao HL, Liu LZ, Sui Y, Ho SK, Tam SK, Lai
FM, Chan JC and Tong PC: Fatty acids inhibit insulin-mediated
glucose transport associated with actin remodeling in rat L6 muscle
cells. Acta Diabetol. 47:331–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bailey T: Options for combination therapy
in type 2 diabetes: comparison of the ADA/EASD position statement
and AACE/ACE algorithm. Am J Med. 126:S10–S20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho YM and Kieffer TJ: New aspects of an
old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer
and sensitiser. Diabetologia. 54:219–222. 2011. View Article : Google Scholar
|
|
23
|
Rena G, Pearson ER and Sakamoto K:
Molecular mechanism of action of metformin: old or new insights?
Diabetologia. 56:1898–1906. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JO, Lee SK, Jung JH, Kim JH, You GY,
Kim SJ, Park SH, Uhm KO and Kim HS: Metformin induces Rab4 through
AMPK and modulates GLUT4 translocation in skeletal muscle cells. J
Cell Physiol. 226:974–981. 2011. View Article : Google Scholar
|
|
25
|
Lee SK, Lee JO, Kim JH, et al: Metformin
sensitizes insulin signaling through AMPK-mediated PTEN
down-regulation in preadipocyte 3T3-L1 cells. J Cell Biochem.
112:1259–1267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barbero-Becerra VJ, Santiago-Hernandez JJ,
Villegas-Lopez FA, Mendez-Sanchez N, Uribe M and Chavez-Tapia NC:
Mechanisms involved in the protective effects of metformin against
nonalcoholic fatty liver disease. Curr Med Chem. 19:2918–2923.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fullerton MD, Galic S, Marcinko K, et al:
Single phosphorylation sites in Acc1 and Acc2 regulate lipid
homeostasis and the insulin-sensitizing effects of metformin. Nat
Med. 19:1649–1654. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW
and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver
by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling
pathway. Biochem Pharmacol. 85:1330–1340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee HI, Yun KW, Seo KI, Kim MJ and Lee MK:
Scopoletin prevents alcohol-induced hepatic lipid accumulation by
modulating the AMPK-SREBP pathway in diet-induced obese mice.
Metabolism. 63:593–601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimomura I, Matsuda M, Hammer RE,
Bashmakov Y, Brown MS and Goldstein JL: Decreased IRS-2 and
increased SREBP-1c lead to mixed insulin resistance and sensitivity
in livers of lipodystrophic and ob/ob mice. Mol Cell. 6:77–86.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ide T, Shimano H, Yahagi N, et al: SREBPs
suppress IRS-2-mediated insulin signalling in the liver. Nat Cell
Biol. 6:351–357. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao
J, Ding L, Zhang J and Wen A: Pharmacogenetic variation and
metformin response. Curr Drug Metab. 14:1070–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
